Delving into the Latest Updates on 四川辉阳生命工程股份有限公司 with Synapse

An international, multicenter, randomized, double-blind, placebo-controlled, parallel, phase II pilot study to evaluate the efficacy and safety of recombinant super-compound interferon (rSIFN-co) among healthy subjects in close contact with confirmed COVID-19 case(s) and subjects with mild or asymptomatic COVID-19

开始日期2022-09-28

申办/合作机构

四川辉阳生命工程股份有限公司

NCT05485584 / Active, not recruiting临床2期

An International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel, Phase II Pilot Study to Evaluate the Efficacy and Safety of Recombinant Super-compound Interferon (rSIFN-co) Among Healthy Subjects in Close Contact With Confirmed COVID-19 Case(s) and Subjects With Mild or Asymptomatic COVID-19

This is a phase II pilot, international, multicenter, randomized, double-blind, placebo-controlled study that aims to evaluate the safety and preliminary efficacy of rSIFN-co nasal spray in healthy subjects in close contact with confirmed COVID-19 case(s) as well as subjects with mild or asymptomatic COVID-19.

开始日期2022-07-01

申办/合作机构

四川辉阳生命工程股份有限公司

NCT02464007 / Active, not recruiting临床1期

A Phase 1 Study of rSIFN-co for Subjects With Advanced Solid Tumors Where Interferons Are Known to Have Demonstrated Antitumor Activity

In this EffTox dose escalation study, up to 3 dose levels will be tested. The optimal dose (OD) of rSIFN-co will be determined using the EffTox design. Additional subject cohorts will not be enrolled until all subjects at the current dose level complete 28 days without DLT. The optimal dose (OD) will be determined by evaluation of safety in each cohort and disease response by RECIST 1.1 at 8 weeks. Once the OD is determined, enrollment will continue until at least 9 subjects total are accrued at the OD. Pharmacokinetics of rSIFN-co will be conducted for all tested dose levels to characterize dose proportionality.

开始日期2016-01-01

申办/合作机构

四川辉阳生命工程股份有限公司

[+1]

100 项与四川辉阳生命工程股份有限公司相关的临床结果

登录后查看更多信息

0 项与四川辉阳生命工程股份有限公司相关的专利（医药）

登录后查看更多信息

2

项与四川辉阳生命工程股份有限公司相关的文献（医药）

2017-04-15·Clinical Cancer Research1区 · 医学

A Potent In Vivo Antitumor Efficacy of Novel Recombinant Type I Interferon

1区 · 医学

Article

作者: Wu, Shuai ; Chen, Lie-Yang ; Liu, Xi-Jun ; Wang, Da-Cheng ; Yin, Xiao-Fei ; Li, Hui-Ling ; Katlinski, Kanstantsin V. ; Guo, Rong-Bing ; Yuan, Su-Jing ; Xiao, Jing ; Liu, Xin-Yuan ; Chu, Liang ; Yang, Yuan-Qin ; Wei, Guang-Wen ; Xu, Hai-Neng ; Fuchs, Serge Y. ; Fang, Xian-Long ; Zhang, Kang-Jian ; Katlinskaya, Yuliya V. ; Xu, Yan-Ni

AbstractPurpose: Antiproliferative, antiviral, and immunomodulatory activities of endogenous type I IFNs (IFN1) prompt the design of recombinant IFN1 for therapeutic purposes. However, most of the designed IFNs exhibited suboptimal therapeutic efficacies against solid tumors. Here, we report evaluation of the in vitro and in vivo antitumorigenic activities of a novel recombinant IFN termed sIFN-I.Experimental Design: We compared primary and tertiary structures of sIFN-I with its parental human IFNα-2b, as well as affinities of these ligands for IFN1 receptor chains and pharmacokinetics. These IFN1 species were also compared for their ability to induce JAK–STAT signaling and expression of the IFN1-stimulated genes and to elicit antitumorigenic effects. Effects of sIFN-I on tumor angiogenesis and immune infiltration were also tested in transplanted and genetically engineered immunocompetent mouse models.Results: sIFN-I displayed greater affinity for IFNAR1 (over IFNAR2) chain of the IFN1 receptor and elicited a greater extent of IFN1 signaling and expression of IFN-inducible genes in human cells. Unlike IFNα-2b, sIFN-I induced JAK–STAT signaling in mouse cells and exhibited an extended half-life in mice. Treatment with sIFN-I inhibited intratumoral angiogenesis, increased CD8+ T-cell infiltration, and robustly suppressed growth of transplantable and genetically engineered tumors in immunodeficient and immunocompetent mice.Conclusions: These findings define sIFN-I as a novel recombinant IFN1 with potent preclinical antitumorigenic effects against solid tumor, thereby prompting the assessment of sIFN-I clinical efficacy in humans. Clin Cancer Res; 23(8); 2038–49. ©2016 AACR.

2016-07-01·Protein & Cell

Interferon-related secretome from direct interaction between immune cells and tumor cells is required for upregulation of PD-L1 in tumor cells

Letter

作者: Wang, Jiao-Jiao ; Xiao, Jing ; Yuan, Su-Jing ; Xu, Yan-Ni ; Yang, Yu ; Zhou, Xiu-Mei ; Dong, Wen-Jie ; Yin, Xiao-Fei ; Fang, Ling ; Liu, Xin-Yuan ; Zhang, Kang-Jian ; Yang, Yuan-Qin ; Xu, Hai-Neng ; DeLong, Jonathan Howard ; Wang, Ru-Wei ; Chu, Liang

100 项与四川辉阳生命工程股份有限公司相关的药物交易

登录后查看更多信息

100 项与四川辉阳生命工程股份有限公司相关的转化医学

登录后查看更多信息